3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
Thoracic
5
Genitourinary
2
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Esophageal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
30
pembrolizumab
24
Magnetic Resonance Spectroscopy
24
Specimen Handling
20
Cetuximab
18
Nivolumab
15
Carboplatin
14
Platinum
12
1,2-diaminocyclohexaneplatinum II citrate
12
Radiotherapy, Intensity-Modulated
11
Radiotherapy
10
Radiation
9
Paclitaxel
9
Docetaxel
8
Biopsy
8
Immunoglobulin G
7
Disulfides
7
Surveys and Questionnaires
6
Ipilimumab
6
atezolizumab
5
Fluorouracil
5
toripalimab
4
dostarlimab
4
cemiplimab
4
cabozantinib
4
Taxes
4
Gemcitabine
4
CTLA-4 Antigen
4
Bevacizumab
4
(225)Ac-DOTA-c(RGDyK)
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
zimberelimab
×
Head & Neck
×
30 days
×
Clear all
NCT05891171
2026-06-05
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled